Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 926.

https://doi.org/10.1182/blood-2019-125871

Published: 2019

Journal Articles

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, MD, Niels Abildgaard, MD, Anna Lysén, MSc, Mona-Elisabeth R Revheim, MD PhD, James P Connelly, MD PhD, Fredrik H. Schjesvold, MD PhD

Blood (2019) 134 (Supplement_1): 3172.

https://doi.org/10.1182/blood-2019-125523

Published: 2019

Journal Articles

The Impact of RVD or VCD Induction on Response 3 Months after First Line Autologous Transplant in Multiple Myeloma. a Single-Center Retrospective Analysis

Magnus Moksnes, MD, Fredrik H. Schjesvold, MD PhD

Blood (2018) 132 (Supplement 1): 3445.

https://doi.org/10.1182/blood-2018-99-113270

Published: 2018

Journal Articles

Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway

Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten

Blood (2018) 132 (Supplement 1): 5759.

https://doi.org/10.1182/blood-2018-99-114474

Published: 2018

Journal Articles

Carfilzomib-Based Regimens Are Efficacious and Well Tolerated in Heavily Pre-Treated Multiple Myeloma Patients: Real World Data from a Norwegian Cohort

Anna Lysén, MSc, Ina Haarstad, MDcal student, Fredrik H. Schjesvold, MD PhD

Blood (2018) 132 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2018-99-110364

Published: 2018

Journal Articles

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Fredrik H. Schjesvold, MD PhD, Geir Erland Tjønnfjord, MD DMsc, Ludvig A Munthe, Kjetil Tasken

Blood (2018) 132 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2018-99-110357

Published: 2018

Journal Articles

Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Mariaserena Giliberto, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Geir Erland Tjønnfjord, MD DMsc, Fredrik H. Schjesvold, MD PhD, Ludvig Andre Munthe, MD PhD, Kjetil Tasken

Blood (2018) 132 (Supplement 1): 4677.

https://doi.org/10.1182/blood-2018-99-110669

Published: 2018

Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Blood (2016) 128 (22): 5692.

https://doi.org/10.1182/blood.V128.22.5692.5692

Published: 2016

Journal Articles

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)

Blood (2016) 128 (22): 242.

https://doi.org/10.1182/blood.V128.22.242.242

Published: 2016

Journal Articles

CSF1R-Inhibition and Reduction of Macrophages Delays Multiple Myeloma Growth in a Non-T-Cell-Dependent Manner

Fredrik H. Schjesvold, MD, Ole Audun Haabeth, MD PhD, Bjarne Bogen, MD PhD, Anders Tveita, MD PhD

Blood (2014) 124 (21): 5717.

https://doi.org/10.1182/blood.V124.21.5717.5717

Published: 2014

NARROW

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

The Impact of RVD or VCD Induction on Response 3 Months after First Line Autologous Transplant in Multiple Myeloma. a Single-Center Retrospective Analysis

Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway

Carfilzomib-Based Regimens Are Efficacious and Well Tolerated in Heavily Pre-Treated Multiple Myeloma Patients: Real World Data from a Norwegian Cohort

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial)

CSF1R-Inhibition and Reduction of Macrophages Delays Multiple Myeloma Growth in a Non-T-Cell-Dependent Manner

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only